Table 3.
Patient cohorts recorded in the chart review
| Cohort A (n = 218) HT 1st line, CT 2nd line, Any Trx 3rd line | Cohort B (n = 26) HT 1st line, HT 2nd line, CT 3rd line | Cohort C (n = 111) CT 1st line, Any Trx 2nd line Any Trx 3rd line | |
|---|---|---|---|
| Average duration of 3 therapy lines, months | 20.9 | 22.9 | 19.7 |
| Breast cancer history at ABC diagnosis, n (%) | |||
| Recurring during adjuvant therapy | 37 (17) | 3 (12) | 30 (27) |
| Recurring ≤1 year after adjuvant therapy | 14 (6) | 2 (8) | 21 (19) |
| Recurring >1 year after adjuvant therapy | 66 (30) | 13 (50) | 38 (34) |
| De novo ABC | 101 (46) | 8 (31) | 22 (20) |
| Adjuvant drug therapies, n (%) | |||
| Any | 102 (47) | 17 (65) | 86 (77) |
| None | 116 (53) | 9 (35) | 25 (23) |
| First-line ABC setting, n (%) | |||
| Hormone therapy | 218 (100) | 26 (100) | 32 (29) |
| Chemotherapy | 0 | 0 | 111 (100) |
| Targeted therapy | 7 (3) | 0 | 24 (22) |
| Second-line ABC setting, n (%) | |||
| Hormone therapy | 18 (8) | 26 (100) | 59 (53) |
| Chemotherapy | 218 (100) | 0 | 65 (59) |
| Targeted therapy | 45 (21) | 1 (4) | 13 (12) |
| Third-line ABC setting, n (%) | |||
| Hormone therapy | 31 (14) | 1 (4) | 12 (11) |
| Chemotherapy | 39 (18) | 26 (100) | 31 (28) |
| Targeted therapy | 10 (5) | 2 (8) | 9 (8) |
| None | 149 (68) | 0 | 73 (66) |
Abbreviation: ABC advanced breast cancer, CT chemotherapy, HT hormone therapy, Trx treatment